Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tucidinostat by HUYA Bioscience International for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Tucidinostat is under clinical development by HUYA Bioscience International and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....
GH-21 by HUYA Bioscience International for Solid Tumor: Likelihood of Approval
GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Solid Tumor. According to GlobalData,...
Tucidinostat by HUYA Bioscience International for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Tucidinostat is under clinical development by HUYA Bioscience International and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....
GH-21 by HUYA Bioscience International for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Head And Neck Squamous Cell...
Tucidinostat by HUYA Bioscience International for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
Tucidinostat is under clinical development by HUYA Bioscience International and currently in Phase II for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy....
Tucidinostat by HUYA Bioscience International for Metastatic Melanoma: Likelihood of Approval
Tucidinostat is under clinical development by HUYA Bioscience International and currently in Phase II for Metastatic Melanoma. According to GlobalData,...
GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval
GH-21 is under clinical development by HUYA Bioscience International and currently in Phase I for Non-Small Cell Lung Cancer. According...